Verdiva Bio
Clinical-stage biotech developing oral and once-weekly peptide therapies for obesity and cardiometabolic disease.
- Biotech & Life Sciences
- Series A
- London
- Sector
- Biotech & Life Sciences
- Stage
- Series A
- Based in
- London
- Founded
- 2024
- Funding raised
- $411M
- Website
- verdivabio.com
Verdiva Bio is a clinical-stage biotechnology company developing peptide medicines for obesity and related cardiometabolic conditions. Its lead candidate, VRB-101, is an oral, once-weekly GLP-1 analogue (ecnoglutide) in Phase 2 development, supported by a pipeline of amylin-based programmes licensed from Sciwind Biosciences. The company launched publicly in January 2025 with more than $410 million in Series A financing co-led by Forbion and General Atlantic, with RA Capital, OrbiMed, Logos Capital, Lilly Asia Ventures and LYFE Capital participating, one of the largest early-stage rounds for a UK biotech. Khurem Farooq is chief executive, and Mark Pruzanski chairs the board. Steve Marso joined as chief medical officer in July 2026.
Team
- Khurem Farooq, Chief Executive Officer
- Jane Hughes, Chief Scientific Officer
- Ashley Taylor, Chief Technology Officer
- Steve Marso, Chief Medical Officer
Backed by
More startups in the directory
Copper
Institutional digital-asset custody, prime brokerage and off-exchange settlement provider.
Cera
Technology-enabled home healthcare provider delivering care, nursing and telehealth across the UK.
Beamery
AI-powered talent lifecycle management platform for large enterprises.
tem
AI-driven platform letting businesses buy clean electricity directly from generators.
PhysicsX
Physics AI platform that accelerates simulation and design for industrial engineering.
Lawhive
AI-enabled online law firm giving consumers and small businesses access to affordable solicitors.
Subscribe to Newsletter
UK startup news, founder stories and funding insight, straight to your inbox every week. Free.